Abstract
Aim
To describe the nature and consequences of the multi-system genetic condition cystic fibrosis with a view to ensuring optimal dental treatment planning for these patients.
Methods
A literature search was conducted to identify the key medical and dental manifestations of cystic fibrosis. These findings are discussed and utilised to create recommendations for treatment planning in patients with cystic fibrosis for the practising dental practitioner.
Results
Cystic fibrosis is a complex, lethal, multisystem autosomal recessive disorder resulting from mutations on chromosome 7 which result in dysfunction of an ion channel that sits on epithelial surfaces. Respiratory disease remains the leading cause of mortality. Survival has greatly increased in recent decades secondary to improved treatment and specialist care. Specific dental manifestations of the disease may result from the condition itself or complications of treatment. Modification of patient management may be necessary to provide optimum patient care.
Conclusion
The pathophysiology and clinical manifestations are relevant to practicing dental practitioners and inform recommendations to be utilised to ensure optimal treatment planning for these patients.
Similar content being viewed by others
References
Alton EW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:684–91.
Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Child. 1938;56:344.
Aps JK, Van Maele GO, Claeys G, Martens LC. Mutans streptococci, lactobacilli and caries experience in cystic fibrosis homozygotes, heterozygotes and healthy controls. Caries Res. 2001;35:407–11.
Azevedo TDPL, Feijó GCS, Bezerra ACB. Presence of developmental defects of enamel in cystic fibrosis patients. J Dent Child. 2006;73:159–63.
Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2014. doi:10.1002/14651858.CD001915.pub4.
Barry PJ, Ronan N, Plant BJ. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning. Semin Respir Crit Care Med. 2015;36:287–98.
Barry S, Fleming P, O’Connor M. Prescribing sugar-containing medicines for children—are we forgetting “primum non nocere?” Ir Med J. 2009;102:298–300.
Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 1992;68:809–18.
Blacharsh C. Dental aspects of patients with cystic fibrosis: a preliminary clinical study. J Am Dent Assoc. 1977;95:106–10.
Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:246–59.
Brennan AL, Beynon J. Clinical updates in cystic fibrosis-related diabetes. Semin Respir Crit Care Med. 2015;36:236–50.
Brihaye P, Jorissen M, Clement PA. Chronic rhinosinusitis in cystic fibrosis (mucoviscidosis). Acta Otorhinolaryngol. 1997;51:323–37.
Chi DL. Dental caries prevalence in children and adolescents with cystic fibrosis: a qualitative systematic review and recommendations for future research. Int J Paediatr Dent. 2013;23(5):376–86.
Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med. 2007;13:529–36.
Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2014. doi:10.1002/14651858.CD002010.pub3.
Dabrowska E, Błahuszewska K, Minarowska A, et al. Assessment of dental status and oral hygiene in the study population of cystic fibrosis patients in the Podlasie province. Adv Med Sci. 2006;51:100–3.
Davies JC, Alton EW, Bush A. Cystic fibrosis. Brit Med J. 2007;335:1255–9.
Di Sant’Agnese PA, Davis PB. Research in cystic fibrosis (first of three parts). N Engl J Med. 1976;295:481–5.
de Oliveira AC, Maluta RP, Stella AE, et al. Isolation of Pseudomonas aeruginosa strains from dental office environments and units in Barretos, state of São Paulo, Brazil, and analysis of their susceptibility to antimicrobial drugs. Braz J Microbiol. 2008;39:579–84.
Döring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11:461–79.
Drury D, Grey VL, Ferland G, Gundberg C, Lands LC. Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. J Cyst Fibros. 2008;7:457–9.
Farzal Z, Kou Y-F, St John R, Shah GB, Mitchell RB. The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: a systematic review. Laryngoscope. 2016;126(1):228–35.
Fernald GW, Roberts MW, Boat TF. Cystic fibrosis: a current review. Pediatr Dent. 1990;12:72–8.
Ferrazzano GF, Sangianantoni G, Cantile T, et al. Dental enamel defects in Italian children with cystic fibrosis: an observational study. Community Dent Health. 2012;29:106–9.
Fox PC. Differentiation of dry mouth etiology. Adv Dent Res. 1996;10:13–6.
Gibson-Corley KN, Meyerholz DK, Engelhardt JF. Pancreatic pathophysiology in cystic fibrosis. J Pathol. 2016;238:311–20.
Gysin C, Alothman GA, Papsin BC. Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management. Pediatr Pulmonol. 2000;30:481–9.
Huffmyer JL, Littlewood KE, Nemergut EC. Perioperative management of the adult with cystic fibrosis. Anesth Analg. 2009;109:1949–61.
Jagels AE, Sweeney EA. Oral health of patients with cystic fibrosis and their siblings. J Dent Res. 1976;55:991–6.
Jensen ET, Giwercman B, Ojeniyi B, et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment. J Hosp Infect. 1997;36:117–22.
Jones AM, Govan JR, Doherty CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet. 2001;358:557–8.
Kessler WR, Andersen DH. Heat prostration in fibrocystic disease of the pancreas and other conditions. Pediatrics. 1951;8:648–56.
Khasawneh FA, Moti DF, Zorek JA. Linezolid-induced black hairy tongue: a case report. J Med Case Rep. 2013;7:46.
Kinirons MJ. Increased salivary buffering in association with a low caries experience in children suffering from cystic fibrosis. J Dent Res. 1983;62:815–7.
Kinirons MJ. Dental health of patients suffering from cystic fibrosis in Northern Ireland. Community Dent Health. 1989;6:113–20.
Kinirons MJ. The effect of antibiotic therapy on the oral health of cystic fibrosis children. Int J Paediatr Dent. 1992;2(3):139–43.
Lewis PA, Morison S, Dodge JA, et al. Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967. The UK Cystic Fibrosis Survey Management Committee. Thorax. 1999;54:420–2.
LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet. 1990;336:1094–6.
MacDonald A. Nutritional management of cystic fibrosis. Arch Dis Child. 1996;74:81–7.
Mainz JG, Gerber A, Lorenz M, et al. Pseudomonas aeruginosa acquisition in cystic fibrosis patients in context of otorhinolaryngological surgery or dentist attendance: case series and discussion of preventive concepts. Case Rep Infect Dis. 2015. doi:10.1155/2015/438517.
Mall MA, Galietta LJV. Targeting ion channels in cystic fibrosis. J Cyst Fibros. 2015;14:561–70.
Mandel ID, Kutscher A, Denning CR, Thompson RH, Zegarelli EV. Salivary studies in cystic fibrosis. Am J Dis Child. 1967;113:431–8.
Mangos JA, Benke PJ, McSherry NR. Salivary gland enlargement and functional changes during feeding of pancreatin to rats (possible relationship to pathophysiology of cystic fibrosis). J Pediatr. 1969;74:823.
Mattsson A. Long-term physical illness in childhood: a challenge to psychosocial adaptation. Pediatrics. 1972;50:801–11.
McCallum TJ, Milunsky JM, Cunningham DL, et al. Fertility in men with cystic fibrosis: an update on current surgical practices and outcomes. Chest. 2000;118:1059–62.
Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680–9.
Molloy L, Nichols K. Infectious diseases pharmacotherapy for children with cystic fibrosis. J Pediatr Health Care. 2015;29:565–78.
Moursi AM, Fernandez JB, Daronch M, Zee L, Jones CL. Nutrition and oral health considerations in children with special health care needs: implications for oral health care providers. Pediatr Dent. 2010;32:333–42.
Narang A, Maguire A, Nunn JH, Bush A. Oral health and related factors in cystic fibrosis and other chronic respiratory disorders. Arch Dis Child. 2003;88:702–7.
O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891–904.
Plant BJ, Goss CH, Plant WD, Bell SC. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med. 2013;1:164–74.
Qvist T, Taylor-Robinson D, Waldmann E, et al. Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros. 2015. doi:10.1016/j.jcf.2015.09.007.
Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–72.
Rashid M, Durie P, Andrew M, et al. Prevalence of vitamin K deficiency in cystic fibrosis. Am J Clin Nutr. 1999;70:378–82.
Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–73.
Schuster A, Shwachman H. The tetracyclines; applied pharmacology. Pediatr Clin North Am. 1956;3:295–303.
Schwank G, Koo B-K, Sasselli V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13:653–8.
Scott RB, O’Loughlin EV, Gall DG. Gastroesophageal reflux in patients with cystic fibrosis. J Pediatr. 1985;106:223–7.
Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45:1160–7.
Stephenson AL, Tom M, Berthiaume Y, et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J. 2015;45:670–9.
Sui W, Boyd C, Wright JT. Altered pH regulation during enamel development in the cystic fibrosis mouse incisor. J Dent Res. 2003;82:388–92.
Sweeney EA, Shaw JH. The effect of dietary pancreatin supplements on dental caries and on the composition of saliva in caries-susceptible rats. J Dent Res. 1965;44:973–6.
Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci. 2009;106:18825–30.
Wainwright BJ, Scambler PJ, Schmidtke J, et al. Localization of cystic fibrosis locus to human chromosome 7cen-q22. Nature. 1985;318:384–5.
Wiesmann UN, Boat TF, Di Sant’Agnese PA. Flow-rates and electrolytes in minor-salivary-gland saliva in normal subjects and patients with cystic fibrosis. Lancet. 1972;2:510–2.
Wotman S, Mercadante J, Mandel ID, Goldman RS, Denning C. The occurrence of calculus in normal children, children with cystic fibrosis, and children with asthma. J Periodontol. 1973;44:278–80.
Acknowledgments
The authors would like to acknowledge the kind contribution of the clinical image by Dr. Rowland Bright-Thomas, Manchester Adult CF Centre.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
PB has received honoraria and financial support for educational activities from Vertex pharmaceuticals Ltd.
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Harrington, N., Barry, P.J. & Barry, S.M. Dental treatment for people with cystic fibrosis. Eur Arch Paediatr Dent 17, 195–203 (2016). https://doi.org/10.1007/s40368-016-0229-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40368-016-0229-9